Nightfood Holdings Inc. (OTCQB: NGTF) announced that its subsidiary, TechForce Robotics, has successfully completed Phase 1 objectives under its joint development agreement with Oncotelic Therapeutics (OTCQB: OTLC), highlighted by the initial deployment of LIM-E, an autonomous laboratory support robot. The deployment marks TechForce's first expansion into pharmaceutical and laboratory automation and validates the adaptability of its AI-enhanced robotics platform beyond hospitality and service-industry applications into life sciences and pharmaceutical environments.
TechForce said the deployment completed the initial operational goals established under the companies' April 2026 collaboration agreement and will provide operational data and workflow insights to support future automation initiatives. The companies plan to continue evaluating opportunities in laboratory logistics, manufacturing support, AI-enhanced workflows and other automation applications, while Nightfood views healthcare, life sciences and pharmaceutical manufacturing as significant long-term growth markets for its Robotics-as-a-Service platform.
The full press release is available at https://ibn.fm/RFkfL.
This milestone demonstrates how TechForce's robotics platform can be applied beyond its original hospitality focus, potentially opening up new revenue streams in high-growth sectors. For Nightfood, which trades under the ticker NGTF, the expansion into pharmaceutical automation could significantly increase the addressable market for its Robotics-as-a-Service model. The company's ability to redeploy its AI-enhanced robotics into laboratory settings suggests a versatile platform that can be adapted to various commercial environments.
Oncotelic Therapeutics, a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, stands to benefit from improved laboratory efficiency through automation. The collaboration may accelerate Oncotelic's research workflows and reduce operational costs, potentially speeding up development timelines for its therapeutic candidates.
For investors, this announcement signals that Nightfood is executing on its strategy to diversify beyond the hospitality sector. The successful deployment of LIM-E provides tangible evidence of the platform's capabilities, which could attract additional partnerships in the life sciences and pharmaceutical industries. As the company collects operational data from this deployment, it will be better positioned to refine its offerings and scale its RaaS model.
More information about Nightfood Holdings is available at www.nightfoodholdings.com, and details about TechForce Robotics can be found at www.techforcerobotics.com. For updates on Oncotelic Therapeutics, visit www.oncotelic.com.
